Codexis (CDXS) to Release Earnings on Thursday

Codexis (NASDAQ:CDXS) is anticipated to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Codexis to post earnings of ($0.16) per share and revenue of $14.5270 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.10. Codexis had a negative net margin of 62.47% and a negative return on equity of 90.51%. The firm had revenue of $38.92 million for the quarter, compared to the consensus estimate of $35.83 million. On average, analysts expect Codexis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Codexis Stock Performance

Shares of NASDAQ CDXS traded up $0.16 during mid-day trading on Tuesday, hitting $2.67. The stock had a trading volume of 957,864 shares, compared to its average volume of 1,968,520. The company has a debt-to-equity ratio of 0.79, a quick ratio of 3.75 and a current ratio of 3.82. The company has a 50 day moving average of $1.81 and a two-hundred day moving average of $1.77. Codexis has a twelve month low of $0.96 and a twelve month high of $3.87. The firm has a market cap of $242.70 million, a PE ratio of -5.13 and a beta of 2.52.

Institutional Investors Weigh In On Codexis

A number of institutional investors have recently added to or reduced their stakes in CDXS. Royal Bank of Canada grew its stake in Codexis by 24.9% in the 1st quarter. Royal Bank of Canada now owns 437,126 shares of the biotechnology company’s stock valued at $1,176,000 after acquiring an additional 87,044 shares during the period. Geode Capital Management LLC boosted its holdings in Codexis by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,869 shares of the biotechnology company’s stock worth $4,827,000 after buying an additional 52,588 shares during the last quarter. Rhumbline Advisers boosted its holdings in Codexis by 25.9% in the 2nd quarter. Rhumbline Advisers now owns 135,556 shares of the biotechnology company’s stock worth $331,000 after buying an additional 27,897 shares during the last quarter. XTX Topco Ltd acquired a new stake in Codexis in the 2nd quarter worth about $116,000. Finally, Invesco Ltd. boosted its holdings in Codexis by 42.4% in the 2nd quarter. Invesco Ltd. now owns 96,078 shares of the biotechnology company’s stock worth $234,000 after buying an additional 28,631 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus set a $5.00 target price on Codexis in a research report on Thursday, March 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Codexis in a research report on Thursday, March 12th. Wall Street Zen downgraded Codexis from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Codexis in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.00.

Codexis Company Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.